Guohua Pan
0000-0003-0309-8413
Publication & Citation Trends
Publications
73 total
Structure-guided design fine-tunes pharmacokinetics, tolerability, and antitumor profile of multispecific frizzled antibodies OA
Cited by 27
Semantic Scholar
Angelicin inhibits liver cancer growth in vitro and in vivo OA
Cited by 22
Semantic Scholar
Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacy.
Cited by 26
Semantic Scholar
The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.
Cited by 65
Semantic Scholar
The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.
Cited by 81
Semantic Scholar
Relationship between expression of CXC chemokine receptor-4 and CXCL12 in gastric cancer and several clinicopathological factors
Cited by 0
Semantic Scholar
Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.
Cited by 38
Semantic Scholar
Synthetic Antibodies with a Human Framework That Protect Mice from Lethal Sudan Ebolavirus Challenge OA
Cited by 29
Semantic Scholar
Research Topics
Cell death mechanisms and regulation
(8)
Atrial Fibrillation Management and Outcomes
(7)
Adipose Tissue and Metabolism
(6)
Microtubule and mitosis dynamics
(5)
Cancer-related Molecular Pathways
(5)
Affiliations
Human Genome Sciences (United States)
Ontario Institute for Cancer Research
University Health Network
Johnson & Johnson (United States)
Janssen (Belgium)